Monitoring of TZM‐HER2 drug‐target engagement and efficacy in tumors with heterogenous TME will be instrumental to improving therapy response and efficacy, by the optimization of targeted delivery in breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.